phrykt

Structure Therapeutics Inc. (GPCR): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of GPCR were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Structure Therapeutics

From the latest filings

Overall: about as much buying as selling. Famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns GPCR

192 funds and institutions reported GPCR shares worth $3.6B at the end of Q2 2026, about 32% of the company. The largest holder is FMR LLC (Fidelity) with 3.7%.

Funds and institutions (13F) 32%Everyone else 68%

10 largest owners, by share of the company

FMR LLC (Fidelity)3.7%
Wellington Management Group LLP3.5%
Avoro Capital Advisors LLC3.1%
Jupiter Topco LLC2.4%
Deep Track Capital, LP2.2%
Bvf Inc1.6%
Morgan Stanley1.3%
Orbimed Advisors LLC1.0%
Principal Financial Group Inc0.8%
American Century Companies Inc0.8%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)7.81M3.66%$419M-7%
Wellington Management Group LLP7.38M3.46%$396M+2%
Avoro Capital Advisors LLC6.56M3.07%$352MNo change
Jupiter Topco LLC5.20M2.44%$279M–
Deep Track Capital, LP4.74M2.22%$254M+11%
Bvf Inc3.37M1.58%$181M-3%
Morgan Stanley2.81M1.32%$151M+22%
Orbimed Advisors LLC2.21M1.04%$119M+50%
Principal Financial Group Inc1.75M0.82%$94.1M-0%
American Century Companies Inc1.68M0.79%$90.3M+17%
Rtw Investments, LP1.61M0.75%$86.3M–
Driehaus Capital Management LLC1.55M0.73%$83.4M-2%
Baker Bros. Advisors LP1.43M0.67%$76.9MNo change
Casdin Capital, LLC1.18M0.55%$63.1MNo change
Deerfield Management Company, L.P.1.09M0.51%$58.3M+41%
Capitolis Liquid Global Markets LLC1.04M0.49%$55.9M-10%
Siren, L.L.C.872,9670.41%$46.9M-34%
T. Rowe Price Associates845,5320.40%$45.4M-58%
Pacific Heights Asset Management LLC800,0000.38%$42.9M+7%
Rock Springs Capital Management LP640,3170.30%$34.4MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No GPCR insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

GPCR short interest

Low short interest. 2.8% of GPCR shares are sold short: about 1 share in 36. Over the last 12 reports the number of shares short went up 5%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 5.93M GPCR shares were sold short, 2.8% of the shares outstanding, down 17.1% from the report before. At the average daily volume of 911,823 shares, buying them all back would take about 6.5 trading days (days to cover).

Shares short, % of all shares

2.77%May 15Oct 303.66%

Days to cover

6.5May 15Oct 3012.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20265.93M2.77%-17%911,8236.5
Oct 15, 20267.15M3.34%-5%1.50M4.8
Sep 30, 20267.54M3.52%+14%1.46M5.2
Sep 15, 20266.61M3.09%+13%1.26M5.2
Aug 31, 20265.85M2.74%-4%740,1857.9
Aug 14, 20266.08M2.84%+0%585,76310.4
Jul 31, 20266.05M2.83%-3%528,50611.4
Jul 15, 20266.21M2.91%+1%703,3178.8
Jun 30, 20266.13M2.87%+4%978,0556.3
Jun 15, 20265.89M2.76%+6%826,2517.1
May 29, 20265.57M2.61%-1%618,0359.0
May 15, 20265.65M2.65%-5%770,6327.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Structure Therapeutics company events

Structure Therapeutics filed 11 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Sep 8, 2026AnnouncementThe Company reported positive topline data for ACCG-2671, an oral, non-peptide, small molecule dual amylin and calcitonin receptor agonist (DACRA), from the SAD portion of the Phase 1/2a clinical trial. Filing
  3. Aug 6, 2026ResultsReleased financial results. Filing
  4. Jun 18, 2026VoteReported shareholder vote results. Filing
  5. May 7, 2026AgreementStructure Therapeutics Inc. amended and restated that certain Sales Agreement dated August 6, 2025 (the “Sales Agreement” and as amended and restated, the “Amended and Restated Sales Agreement”) with Leerink Partners LLC and Cantor Fitzgerald & Co., relating to the offer and sale of the Company’s… Filing
  6. Apr 15, 2026LeadershipDeparture of Director or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Filing
  7. Mar 16, 2026AnnouncementACCESS II Study - Evaluating higher doses up to 240 mg ACCESS II is a randomized, double-blind, placebo-controlled, clinical study of aleniglipron that enrolled 85 adult participants living with obesity or overweight (defined as a BMI of greater than 25 kg/m2) with at least one weight-related… Filing
  8. Feb 26, 2026ResultsReleased financial results. Filing
  9. Jan 5, 2026AgreementGasherbrum Bio, Inc., a wholly-owned subsidiary of Structure Therapeutics Inc., entered into an agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd that was the culmination of discussions initiated by Genentech’s inquiry regarding the availability of a license to certain patents of… Filing
  10. Dec 10, 2025AnnouncementStructure Therapeutics, Inc. entered into an underwriting agreement with Jefferies LLC, Leerink Partners LLC, Goldman Sachs & Co. LLC and Morgan Stanley & Co. LLC, as representatives of the several underwriters named therein, pursuant to which the Company agreed to issue and sell in an underwritten… Filing
  11. Dec 8, 2025AnnouncementSummary of Data from the ACCESS Clinical Program The Company’s ACCESS clinical program includes 36-week data from the core Phase 2b ACCESS study and exploratory ACCESS II study, and interim data from Phase 2 body composition study and Phase 2b ACCESS open label extension (OLE) study, as follows: •… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Structure Therapeutics financials

Famous investors that hold GPCR

3 of the 50 well-known investors we track reported holding GPCR in their latest 13F filing. The largest position is Ken Griffin's, worth $3.6M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 2026116,295$3.6M0.0%New
Israel Englander · Millennium ManagementQ3 202680,675$2.5M0.0%-10%
Paul Tudor Jones · Tudor Investment CorpQ3 202612,639$395K0.0%-76%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named GPCR in the last 120 days.

FiledHolderFormStake
Nov 16, 2026Deep Track Capital, LP13G/A7.2%
Nov 16, 2026Wellington Management Group LLP13G/A13.6%
Nov 16, 2026Deep Track Capital, LP13G/A7.2%
Nov 16, 2026Wellington Management Group LLP13G/A13.6%
Nov 5, 2026FMR LLC13G/A15.0%
Nov 5, 2026FMR LLC13G/A15.0%

Questions about Structure Therapeutics Inc. (GPCR) stock

Who owns the most GPCR stock?

The largest reported owner of Structure Therapeutics Inc. (GPCR) is FMR LLC (Fidelity), with 3.7% of the company. In total, 192 funds and institutions reported holding GPCR at the end of Q2 2026, together about 32% of the shares. See the largest owners.

Are GPCR insiders buying or selling?

No GPCR insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in GPCR?

As of Oct 30, 2026, 5.93M GPCR shares were sold short, 2.8% of the shares outstanding, down 17.1% from the report before. At the average daily volume of 911,823 shares, buying them all back would take about 6.5 trading days (days to cover). See the history.

Which famous investors hold GPCR?

3 of the 50 well-known investors we track reported GPCR in their latest 13F filing, including Ken Griffin, Israel Englander, Paul Tudor Jones. The largest position is worth $3.6M. See all holders.

Executive pay

Structure Therapeutics's chief executive was paid a total of $8.4M for the year ended Dec 31, 2025, up 47% from $5.7M the year before. In the last 12 months, Structure Therapeutics's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$8.4MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$36.2MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$3MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.